Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,570.00
Ask: 1,680.00
Change: 0.00 (0.00%)
Spread: 110.00 (7.006%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,599.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Taihua Total Sales Up For 2014 As Price Increase Offsets Lower Harvest

Thu, 19th Feb 2015 11:41

LONDON (Alliance News) - Taihua PLC Thursday said its total sales rose to CNY53.1 million from CNY2.3 million in 2013, as the wholesale price of forsythia compensated for a reduced harvest.

Taihua is a China based pharmaceutical company specialising in traditional Chinese medicine and some active pharmaceutical ingredients.

The company saw a total harvest of 1,145 tonnes of forsythia, down from 1,528.6 tonnes in the previous year, due to adverse weather conditions. The company said other suppliers saw a similar shortfall which helped increase wholesale prices.

The average selling price rose to CNY37.77 per kilogram from CNY28.31 per kilogram excluding sales tax. The entire harvest was sold.

Taihua said it was still seeking to extend the distribution of Chinese traditional medicine Bian Tong Pian. At the time of its interim results, the company said it had been unable to extend distribution of Bian Tong Pian due to the impact of the GlaxoSmithKline PLC bribery allegations in China.

"The problems surrounding GlaxoSmithKline in China and associated investigations into the distribution of pharmaceuticals by the Chinese government has left distributors reluctant to take on new products. For the time being, given the government focus on this industry, they prefer to adopt a very conservative approach and only distribute their existing products," it said at the time.

The company said Thursday that the profitability of its active pharmaceutical ingredient paclitaxel has been reduced, and in 2014 it was loss-making at a gross margin levels as by-products had not been successfully sold. As a result, it will cease production of paclitaxel for an initial six months with immediate effect.

After this time, it will assess what the withdrawal from production has done to the Chinese wholesale price, and then make a further decision on the future of the product.

Sales of ingredient homoharringtonine continued at the low level it has seen in recent years, it said. However, Taihua will continue to produce the ingredient as historically the product has been important due to its volume and margin, and it expects a return to earlier market conditions.

Taihua said it was working with agronomists to look for ways to enhance the harvest from its plantations.

Shares in Taihua are trading up 6.7% at 4.00 pence Thursday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 08:37

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Read more
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more
1 Sep 2023 07:49

LONDON BRIEFING: Stocks seen higher; UK house prices continue to fall

(Alliance News) - Stocks in London are set to open higher on Friday as markets looked ahead to a data-heavy day.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.